Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET.

PURPOSE Hepatocyte growth factor/scatter factor (HGF/SF) is known to increase the invasiveness and migration of cancer cells in vitro and induce angiogenesis. This study examined if inhibition of HGF/SF receptor expression by cancer cells and HGF/SF expression by stromal fibroblasts affects the growth of mammary cancer. EXPERIMENTAL DESIGN Transgenes encoding ribozymes to specifically target human HGF/SF receptor (pLXSN-MET) or HGF/SF (pLXSN-HGF) were constructed using a pLXSN retroviral vector. Human mammary cancer cells MDA MB 231 was transduced with pLXSN-MET (MDA(+/+)). A human fibroblast cell line MRC5, which produces bioactive HGF/SF, was transduced with pLXSN-HGF (MRC5(+/+)). These cells were used in a nude mice breast tumor model. RESULTS HGF receptor in MDA(+/+) cells and HGF in MRC5(+/+)cells were successfully removed with respective ribozymes as shown by reverse transcription-PCR and Western blotting, respectively. MDA(+/+) was found to have reduced invasiveness when stimulated with HGF/SF. MRC5(+/+) exhibited a significant reduction in HGF/SF production. When injected into athymic nude mice, MDA(+/+) exhibited a slower rate of growth, compared with the wild type (MDA(-/-)), and the cells transduced with control viral vector (MDA(+/-)). The growth of MDA(-/-) tumor was significantly enhanced when coimplanted with wild-type MRC5 (MRC5(-/-)), and the stimulatory effect was reduced when MRC5(+/+) cells were coimplanted instead of MRC5(-/-). The reduction of tumor growth was accompanied by reduction of angiogenesis, as demonstrated by the staining of VE-cadherin in primary tumor tissues. CONCLUSIONS Retroviral ribozyme transgenes targeting HGF/SF in fibroblasts or its receptor cMET in mammary cancer cells can reduce the growth of mammary cancer and associated angiogenesis by inhibiting paracrine stromal-tumor cell interactions.

[1]  T. Nakamura,et al.  Regulation of spreading and growth of colon cancer cells by hepatocyte growth factor , 1993, Clinical & Experimental Metastasis.

[2]  T. Nakamura,et al.  Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. , 2003, Carcinogenesis.

[3]  B. Davidson,et al.  The FASEB Journal express article 10.1096/fj.01-0421fje. Published online November 29, 2001. , 2022 .

[4]  A. Giuliano,et al.  Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. , 2001, Cancer research.

[5]  I. Tsarfaty,et al.  Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model. , 2000, Cytometry.

[6]  谷浦 直子 Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts , 2000 .

[7]  G. Bratthauer,et al.  Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. , 2000, Cancer research.

[8]  E. Rimm,et al.  Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.

[9]  K. Matsumoto,et al.  Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  I. Bièche,et al.  Alteration of Met protooncogene product expression and prognosis in breast carcinomas. , 1999, Analytical and quantitative cytology and histology.

[11]  H. Dietz,et al.  Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. , 1999, Journal of the National Cancer Institute.

[12]  M. Sasaki,et al.  Mammary fibroblast-derived hepatocyte growth factor and mammogenic hormones stimulate the growth of mouse mammary epithelial cells in primary culture. , 1999, Endocrine journal.

[13]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. , 1999, Critical reviews in oncology/hematology.

[14]  M. Sasaki,et al.  Mammary Fibroblast‐derived Hepatocyte Growth Factor Stimulates Growth and Morphogenesis of Mouse Mammary Tumor Cells in Primary Culture , 1998, Japanese journal of cancer research : Gann.

[15]  J. Horiguchi,et al.  Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. , 1998, Cancer letters.

[16]  E. Rimm,et al.  Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.

[17]  N. Funata,et al.  Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  M. Toi,et al.  Serum hepatocyte growth factor levels in breast cancer patients with distant metastases , 1998 .

[19]  K. Matsumoto,et al.  Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. , 1997, Cancer research.

[20]  R. Mansel,et al.  Regulation of the Expression of E-Cadherin on Human Cancer Cells by γ-Linolenic Acid (GLA) , 1995 .

[21]  T. Imazawa,et al.  Serum concentrations of hepatocyte growth factor in breast cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  R. Mansel,et al.  Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). , 1995, Cancer research.

[23]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. , 1994, The Journal of biological chemistry.

[24]  M. Bhargava,et al.  Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor , 1994, International journal of cancer.

[25]  M. Ogawa,et al.  Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. , 1994, Cancer research.

[26]  T. Nakamura,et al.  Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. , 1993, Cancer research.

[27]  H. Kleinman,et al.  Scatter factor induces blood vessel formation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  W. Jiang,et al.  Monocyte‐conditioned media possess a novel factor which increases motility of cancer cells , 1993, International journal of cancer.

[29]  L. Naldini,et al.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.

[30]  E. Gherardi,et al.  Hepatocytes and scatter factor , 1990, Nature.

[31]  K. Tashiro,et al.  Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.

[32]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.